Antifungal prophylaxis in liver transplant recipients.
Although the overall incidence of fungal infections in liver transplant recipients has declined, these infections still contribute significantly to the morbidity and mortality of patients with risk factors for infection. Although antifungal prophylaxis has been widely studied and practiced, no consensus exists on which patients should receive prophylaxis, with which agent, and for what duration. Numerous studies have attempted to ascertain independent risk factors for invasive fungal infections in liver transplant patients, and these data, in addition to clinical trials, identify several patient groups at exceedingly high risk of fungal infection. These include retransplant patients, patients with renal failure requiring hemodialysis or renal replacement therapy, and those requiring reoperations after transplant. Because the majority of infections occur in the first month after transplantation, prophylaxis should be continued for 4-6 weeks. However, local epidemiology and research should guide decisions regarding choice of agent as well as overall development of interinstitutional guidelines, because the incidence and spectrum of infection may differ dramatically among institutions. Liver Transpl 15:842-858, 2009. (c) 2009 AASLD.
Eschenauer
Gregory A
GA
University of Pittsburgh Medical Center, Pittsburgh, PA, USA. eschenauerg@upmc.edu
Lam
Simon W
SW
Carver
Peggy L
PL
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000209:etiology; D001230:Aspergillus / Q000378:metabolism; D002986:Clinical Trials as Topic; D003587:Cytomegalovirus / Q000378:metabolism; D003586:Cytomegalovirus Infections / Q000209:etiology; D004781:Environmental Exposure; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods*; D008297:Male; D009181:Mycoses / Q000150:complications*; D011183:Postoperative Complications; D012307:Risk Factors; D016896:Treatment Outcome
D000935:Antifungal Agents